Inari Medical, Inc. (NASDAQ:NARI) Director Sells $565,460.00 in Stock

Inari Medical, Inc. (NASDAQ:NARIGet Rating) Director Donald B. Milder sold 7,000 shares of the stock in a transaction on Monday, August 15th. The stock was sold at an average price of $80.78, for a total transaction of $565,460.00. Following the completion of the sale, the director now owns 3,206,614 shares in the company, valued at $259,030,278.92. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Inari Medical Stock Down 3.5 %

Inari Medical stock traded down $2.77 during mid-day trading on Wednesday, reaching $76.28. The company’s stock had a trading volume of 682,559 shares, compared to its average volume of 625,224. Inari Medical, Inc. has a 12 month low of $50.50 and a 12 month high of $100.00. The business’s 50 day simple moving average is $72.69 and its 200 day simple moving average is $76.52.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in the business. Trustcore Financial Services LLC grew its position in shares of Inari Medical by 266.7% in the 1st quarter. Trustcore Financial Services LLC now owns 275 shares of the company’s stock valued at $25,000 after acquiring an additional 200 shares during the period. Parkside Financial Bank & Trust bought a new position in shares of Inari Medical in the 1st quarter valued at about $25,000. Fifth Third Bancorp bought a new position in shares of Inari Medical in the 2nd quarter valued at about $27,000. C M Bidwell & Associates Ltd. bought a new position in shares of Inari Medical in the 4th quarter valued at about $49,000. Finally, DB Wealth Management Group LLC bought a new position in shares of Inari Medical in the 1st quarter valued at about $54,000. Institutional investors own 67.90% of the company’s stock.

Analysts Set New Price Targets

Several research firms have weighed in on NARI. Morgan Stanley cut their target price on shares of Inari Medical from $108.00 to $93.00 and set an “overweight” rating on the stock in a report on Friday, July 15th. Piper Sandler began coverage on shares of Inari Medical in a research report on Tuesday, June 21st. They set an “overweight” rating and a $100.00 price objective for the company. Finally, BTIG Research lowered their price objective on shares of Inari Medical from $130.00 to $100.00 and set a “buy” rating for the company in a research report on Friday, June 24th. Six equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company has a consensus rating of “Buy” and an average target price of $96.67.

Inari Medical Company Profile

(Get Rating)

Inari Medical, Inc, a medical device company, develops, manufactures, markets, and sells devices for the interventional treatment of venous diseases in the United States. The company provides ClotTriever, a mechanical thrombectomy system, which is designed to core, capture, and remove large clots from large vessels, as well as for treatment of deep vein thrombosis; and FlowTriever, a large bore catheter-based aspiration and mechanical thrombectomy system, for treatment of pulmonary embolism.

Featured Articles

Insider Buying and Selling by Quarter for Inari Medical (NASDAQ:NARI)

Receive News & Ratings for Inari Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inari Medical and related companies with MarketBeat.com's FREE daily email newsletter.